Brokerages expect The Clorox Company (NYSE:CLX – Get Rating) to report sales of $1.87 billion for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Clorox’s earnings. The highest sales estimate is $1.89 billion and the lowest is $1.85 billion. Clorox posted sales of $1.80 billion during the same quarter last year, which suggests a positive year over year growth rate of 3.9%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Clorox will report full-year sales of $7.18 billion for the current fiscal year, with estimates ranging from $7.16 billion to $7.19 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $7.47 billion, with estimates ranging from $7.39 billion to $7.60 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Clorox.
Clorox (NYSE:CLX – Get Rating) last released its quarterly earnings data on Monday, May 2nd. The company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.34. Clorox had a return on equity of 92.98% and a net margin of 6.44%. The business had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.81 billion. During the same quarter in the previous year, the firm posted $1.62 EPS.
In related news, COO Eric H. Reynolds sold 585 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $154.83, for a total value of $90,575.55. Following the completion of the transaction, the chief operating officer now directly owns 17,289 shares in the company, valued at approximately $2,676,855.87. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.58% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in the stock. Dark Forest Capital Management LP bought a new position in shares of Clorox during the third quarter valued at approximately $25,000. Eagle Bay Advisors LLC purchased a new stake in shares of Clorox during the third quarter valued at $26,000. Newbridge Financial Services Group Inc. boosted its stake in shares of Clorox by 185.2% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 154 shares of the company’s stock valued at $27,000 after purchasing an additional 100 shares during the period. TAP Consulting LLC purchased a new stake in shares of Clorox during the fourth quarter valued at $27,000. Finally, FSB Premier Wealth Management Inc. purchased a new stake in shares of Clorox during the fourth quarter valued at $28,000. 77.28% of the stock is owned by hedge funds and other institutional investors.
CLX opened at $146.40 on Friday. Clorox has a one year low of $127.02 and a one year high of $191.75. The company has a debt-to-equity ratio of 3.28, a quick ratio of 0.40 and a current ratio of 0.71. The stock’s fifty day moving average is $145.41 and its 200-day moving average is $156.18. The company has a market capitalization of $18.02 billion, a PE ratio of 39.67, a P/E/G ratio of 4.74 and a beta of 0.18.
About Clorox (Get Rating)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.
- Get a free copy of the StockNews.com research report on Clorox (CLX)
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.